Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takuya Sho

Showing results (81-90 of 120) with videos related to

Pageof 12
Sort By:
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 13, 2016
Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairmentGoki Suda, Atsushi Nagasaka, Yoshiya Yamamoto, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 10, 2018
Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunctionTakuya Sho, Goki Suda, Atsushi Nagasaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 30, 2022
Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon-lambda 3 induction in chronic hepatitis B patientsMachiko Umemura, Koji Ogawa, Kenichi Morikawa, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 21, 2020
Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteriaTakuya Sho, Goki Suda, Koji Ogawa, et al.
Frontiers in Genetics|May 23, 2022
Case Report: Hereditary Fibrosing Poikiloderma With Tendon Contractures, Myopathy, and Pulmonary Fibrosis (POIKTMP) Presenting With Liver Cirrhosis and Steroid-Responsive Interstitial PneumoniaMichiko Takimoto-Sato, Toshinari Miyauchi, Masaru Suzuki, et al.
Alimentary Pharmacology & Therapeutics|September 4, 2024
Positivity of high-sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non-HBV-related HCCNaohiro Yasuura, Goki Suda, Masatsugu Ohara, et al.
Scientific Reports|October 7, 2022
Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapyNaoki Kawagishi, Goki Suda, Ryotaro Sakamori, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|February 15, 2020
Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world settingTakuya Sho, Goki Suda, Koji Ogawa, et al.
Scientific Reports|November 29, 2025
Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohortGoki Suda, Masaru Baba, Yoshiya Yamamoto, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 10, 2021
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteriaTakuya Sho, Goki Suda, Koji Ogawa, et al.
Pageof 12

Showing results (81-90 of 120) with videos related to

Sort By:
Pageof 12
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 13, 2016
Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairmentGoki Suda, Atsushi Nagasaka, Yoshiya Yamamoto, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 10, 2018
Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunctionTakuya Sho, Goki Suda, Atsushi Nagasaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 30, 2022
Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon-lambda 3 induction in chronic hepatitis B patientsMachiko Umemura, Koji Ogawa, Kenichi Morikawa, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 21, 2020
Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteriaTakuya Sho, Goki Suda, Koji Ogawa, et al.
Frontiers in Genetics|May 23, 2022
Case Report: Hereditary Fibrosing Poikiloderma With Tendon Contractures, Myopathy, and Pulmonary Fibrosis (POIKTMP) Presenting With Liver Cirrhosis and Steroid-Responsive Interstitial PneumoniaMichiko Takimoto-Sato, Toshinari Miyauchi, Masaru Suzuki, et al.
Alimentary Pharmacology & Therapeutics|September 4, 2024
Positivity of high-sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non-HBV-related HCCNaohiro Yasuura, Goki Suda, Masatsugu Ohara, et al.
Scientific Reports|October 7, 2022
Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapyNaoki Kawagishi, Goki Suda, Ryotaro Sakamori, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|February 15, 2020
Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world settingTakuya Sho, Goki Suda, Koji Ogawa, et al.
Scientific Reports|November 29, 2025
Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohortGoki Suda, Masaru Baba, Yoshiya Yamamoto, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 10, 2021
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteriaTakuya Sho, Goki Suda, Koji Ogawa, et al.
Pageof 12